Key result
Ibutilide converted atrial fibrillation in 55% of patients, with higher success in those with coronary artery disease and without mitral valve disease or enlarged left atrium.
Why the study?
What are the clinical and echocardiographic predictors of successful cardioversion of atrial fibrillation with ibutilide?
Observational (n=101)
What are the clinical and echocardiographic predictors of successful cardioversion of atrial fibrillation with ibutilide?
Ibutilide is most effective for cardioversion of atrial fibrillation in patients with coronary artery disease and those without mitral valve disease or markedly enlarged left atrium.
Answers are grounded in this paper and cite their sources.
Ibutilide may succeed more often in CAD without mitral valve disease; leaves open prospective validation before guiding selection.
BACKGROUND: Atrial fibrillation (AF) is found in 1% of persons above the age of 60 years. More than 5% of the population older than 69 years and about 14% of octogenarians are at risk for this arrhythmia. It is estimated that 1.5 to 3 million persons in the United States alone suffer from AF. The public health implications and attendant morbidity are a significant drain on our health care system. HYPOTHESIS: The purpose of this study was to determine the clinical and echocardiographic predictors of success in converting AF of > or = 24 h duration. METHODS: Demographic and clinical and echocardiographic parameters of 101 patients with recent onset AF (> 24 h) who received ibutilide were studied. RESULTS: Of 101 patients, 56 (55%) converted to sinus rhythm. Age, gender, hypertension, diabetes mellitus, left ventricular ejection fraction (< or = 35%), congestive heart failure, and previous medication for rate control had no significant effect on the conversion rate. Conversion rate was only 30% (9/30 patients) in the presence of an enlarged left atrium (LA > or = 5 cm) and 37.7% (23/61 patients) in the presence of mitral valve disease (MVD), whereas the conversion rate was 82.5% (33/40 patients) in the absence of MVD and 85% (29/34 patients) in the absence of both enlarged LA and MVD (p = <0.001). Patients with coronary artery disease (CAD) also exhibited a significantly greater response to ibutilide than patients without CAD (77 vs. 46%, p-value 0.005). CONCLUSION: As a therapy for cardioversion of AF, ibutilide is most effective in a selected subgroup patients, such as in patients with CAD and in patients without MVD and/or markedly enlarged left atrium.
No takes yet. Share an insight, caveat, or question.
Das et al. (2002) conducted an observational in Atrial fibrillation (n=101). Ibutilide was evaluated on Conversion to sinus rhythm. Ibutilide converted atrial fibrillation in 55% of patients, with higher success in those with coronary artery disease and without mitral valve disease or enlarged left atrium.
Synapse has enriched 10 related papers. Consider them for comparative context: